Cytochalasin B, Inhibitor

Cytochalasin B

Cat. Num. AAA5758286

• Purity: 98.00%
• Synonyms: Cytochalasin B; Phomin; inhibitor

• Purity/Purification: 98.00%
• Form/Format: Solid. Powder

• Solubility: DMSO: 20mg/mL (41.7mM); Ethanol: 20mg/mL (41.7mM); (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: C29H37NO5
• SMILES: C[C@@H]([C@@H]([C@H](Cc1ccccc1)NC1=O)[C@@]1([C@H]([C@@H]1O)/C=C/C[C@H](C)CCC[C@H](/C=C2)O)OC2=O)C1=C
• CAS Number: 14930-96-2
• Cell Research: The attached cell lines M109c, B16BL6, and B16F10 are seeded at 1 to 4x10^4 cells/mL in 2mL volumes in 24-well culture plates 1 day prior to treatment with Cytochalasin B. The suspension culture of P388/ADR cells is seeded at 5x10^4 cells/mL and allowed to grow overnight before Cytochalasin B treatment, Cells are treated with Cytochalasin B for 3 h, as well as 2, 3, or 4 days. In the case of continuous exposure for 2, 3, or 4 days, attached cells are trypsinized and counted with a hemacytometer. Leukemia cell suspensions are counted with a Coulter Counter. In the case of short-term exposure, cells are washed twice with fresh medium, then trypsinized (except for P388/ADR cells), reseeded, and allowed to regrow for 3 days, at which time they are counted. Growth results are calculated as the number of cells generated above the seeding density compared to the untreated control cells and graphically presented as a percent of control increase [3].
• In Vitro: Cytochalasin B (10, 25, 50mg/kg, i.p.) dose-dependently increases the life expectancy of Balb/c mice bearing with P388/ADR leukemias. Cytochalasin B at 50mg/kg produces 10% long-term survival in the multidrug-resistant P388/ADR cohort, and 40% long-term survival in the drug-sensitive P388/S cohort [3].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Related Product Information for Cytochalasin B, inhibitor

Cytochalasin B is a mycotoxin binding to the barbed end of actin filaments. It can disrupt the formation of actin polymers (Kd: 1.4-2.2nM for F-actin).

Product Categories/Family for Cytochalasin B, inhibitor

Cytoskeletal Signaling

References

Theodoropoulos PA, et al. Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping. Biochem Pharmacol. 1994 May 18;47(10):1875-81.
Theodoropoulos PA, et al. Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping. Biochem Pharmacol. 1994 May 18;47(10):1875-81.
Zhou C, et al. The effect of Cytochalasin B and Jasplakinolide on depolymerization of actin filaments in goose muscles during postmortem conditioning. Food Res Int. 2016 Dec;90:1-7.
Zhou C, et al. The effect of Cytochalasin B and Jasplakinolide on depolymerization of actin filaments in goose muscles during postmortem conditioning. Food Res Int. 2016 Dec;90:1-7.
Trendowski M, et al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9.
Trendowski M, et al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9.